Get the Stockscreener App
4.72
1.94%
+0.09
TELA Bio Inc stock is currently priced at $4.72, with a 24-hour trading volume of 29,752.
It has seen a +1.94% increased in the last 24 hours and a -10.94% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.63 pivot point. If it approaches the $4.79 resistance level, significant changes may occur.
Previous Close:
$4.63
Open:
$4.71
24h Volume:
29,752
Market Cap:
$116.37M
Revenue:
$53.08M
Net Income/Loss:
$-43.75M
P/E Ratio:
-2.0978
EPS:
-2.25
Net Cash Flow:
$-42.24M
1W Performance:
+6.07%
1M Performance:
-10.94%
6M Performance:
-18.90%
1Y Performance:
-50.32%
1D Range:
$4.65
$4.79
52W Range:
$4.2349
$11.26
TELA Bio Inc Stock (TELA) Company Profile
Name
TELA Bio Inc
Sector
Industry
Phone
484 320 2930
Address
1 Great Valley Parkway, Suite 24, Malvern, PA
TELA Bio Inc Stock (TELA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-22 | Initiated | Lake Street | Buy |
| Dec-03-19 | Initiated | Canaccord Genuity | Buy |
| Dec-03-19 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-19 | Initiated | Jefferies | Buy |
| Dec-03-19 | Initiated | Piper Jaffray | Overweight |
TELA Bio Inc Stock (TELA) Latest News
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
GlobeNewswire Inc.
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
Zacks Investment Research
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
GlobeNewswire Inc.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
GlobeNewswire Inc.
TELA Bio Inc Stock (TELA) Financials Data
TELA Bio Inc (TELA) Revenue 2024
TELA reported a revenue (TTM) of $53.08 million for the quarter ending September 30, 2023, a +39.05% rise year-over-year.
TELA Bio Inc (TELA) Net Income 2024
TELA net income (TTM) was -$43.75 million for the quarter ending September 30, 2023, a -1.90% decrease year-over-year.
TELA Bio Inc (TELA) Cash Flow 2024
TELA recorded a free cash flow (TTM) of -$42.24 million for the quarter ending September 30, 2023, a -4.38% decrease year-over-year.
TELA Bio Inc (TELA) Earnings per Share 2024
TELA earnings per share (TTM) was -$2.06 for the quarter ending September 30, 2023, a +27.97% growth year-over-year.
TELA Bio Inc Stock (TELA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KOBLISH ANTONY | Chief Executive Officer |
Nov 14 '23 |
Buy |
4.54 |
11,000 |
49,976 |
303,634 |
| Cuca Roberto | COO and CFO |
Nov 14 '23 |
Buy |
4.49 |
10,000 |
44,938 |
62,371 |
About TELA Bio Inc
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.
0.77%
Cap:
|
Volume (24h):